Bibliographie collaborative AIH – Juin 2016

Hémopathie bégnine

Proposé par Milena Kohn et Vincent Allain, supervisé par Louis Terriou

  1. Zhang X, Dai R, Li W, et al. Abnormalities of follicular helper T-cell number and function in Wiskott-Aldrich syndrome. Blood. 2016 Jun 23;127(25):3180-91.
  1. Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Jul 2;388(10039):45-54.
  1. Patriquin CJ, Thomas MR, Dutt T, et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2016 Jun;173(5):779-85.
  1. Mariotte E, Azoulay E, Galicier L, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016 May;3(5):e237-45.
  1. Mahévas M, Michel M, Godeau B. How we manage immune thrombocytopenia in the elderly. Br J Haematol. 2016 Jun;173(6):844-56.
  1. Janda A, Schwarz K, van der Burg M, et al. Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome. Blood. 2016 May 5;127(18):2193-202
  1. Hubbard N, Hagin D, Sommer K, et al. Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. Blood. 2016 May 26;127(21):2513-22
  1. Dufour C, Miano M, Fioredda F. Old and new faces of neutropenia in children. Haematologica. 2016 Jul;101(7):789-91.
  1. Thomas MR, Robinson S, Scully MA. How we manage thrombotic microangiopathies in pregnancy. Br J Haematol. 2016 Jun;173(6):821-30.
  1. Sekiguchi H, Horei R, Kanai M et al. Immunoglobulin G4-Related Disease: Retrospective Analysis of 166 Patients. Arthritis Rheumatol. 2016 Mar 18 ; 68, 3.



Proposé par Zoé Van de Wyngaert et Dinh Ngoc Mai, supervisé par Régis Peffault de Latour

  1. Hingorani S. Renal Complications of Hematopoietic-Cell Transplantation. The New England journal of medicine. 2016;374(23):2256-67.
  1. Hombach AA, Gorgens A, Chmielewski M, et al. Superior Therapeutic Index in Lymphoma Therapy: CD30+ CD34+ Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack. Mol Ther. 2016 Jun 28.
  1. Mehta RS, Peffault de Latour R, DeFor TE, et al. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. Haematologica. 2016;101(6):764-72.
  1. Nestorowa S, Hamey FK, Pijuan Sala B, et al. A single cell resolution map of mouse haematopoietic stem and progenitor cell differentiation. Blood. 2016 Jun 30.
  1. Palchaudhuri R, Saez B, Hoggatt J, et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nature biotechnology. 2016 Jul;34(7):738-45.
  1. Pierini A, Strober W, Moffett C, et al. TNFalpha priming enhances CD4+FoxP3+ regulatory T cell suppressive function in murine GvHD prevention and treatment. Blood. 2016 Jun 30.
  1. Potter VT, Iacobelli S, van Biezen A, et al. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016 Jun 3.
  1. Sobh M, Michallet M, Gahrton G, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016 May 20.
  1. Wang LD, Ficarro SB, Hutchinson JN, et al. Phosphoproteomic profiling of mouse primary hematopoietic stem and progenitor cells reveals new regulators of HSPC mobilization. Blood. 2016 Jun 30.
  1. Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-26.

Leucémies aiguës

 Proposé par Lucile Debus et Ludovic Gabellier, supervisé par Pierre Hirsch

  1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine. 2016 Jun 9;374(23):2209–21.
  1. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine. 2016 Jun 12.
  1. Jacola LM, Krull KR, Pui C-H, et al. Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol. Journal of Clinical Oncology. 2016 Apr 10;34(11):1239–47
  1. Galloway-Peña JR, Smith DP, Sahasrabhojane P, et al. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia: Microbiome Analyses of Patients With AML. Cancer. 2016 Jul 15;122(14):2186–96.
  1. Williams MTS, Yousafzai YM, Elder A, et al. The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. Blood. 2016 Apr 21;127(16):1998–2006.
  1. Ma HS, Greenblatt SM, Shirley CM, et al. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Blood. 2016 Jun 9;127(23):2867–78.
  1. Jain N, Lamb AV, OBrien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14;127(15):1863–9.
  1. Duployez N, Marceau-Renaut A, Boissel N, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127(20):2451–9.



Proposé par Cédric Rossi et Camille Bigenwald, supervisé par Fabrice Jardin

  1. Hansen HP, Trad A, Dams M, et al. CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro. Oncotarget. 2016 Apr 20.
  1. Carde P, Karrasch M, Fortpied C, et al. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36.
  1. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29.
  1. Böll B, Goergen H, Behringer K, et al.  Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.  Blood.2016 May 5;127(18):2189-92.
  1. Sehn LH, Chua N, Mayer J, et al.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkinlymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.  Lancet Oncol. 2016 Jun 23.
  1. Sarkozy C, Trneny M, Xerri L, et al.  Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. J Clin Oncol. 2016 Aug 1;34(22):2575-82.
  1. Castillo JJ, Beltran BE, Miranda RN, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol.2016 May;91(5):529-37.



 Proposé par Alexis Talbot et Floriane Theves, supervisé par Laurent Frenzel

  1. Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-34.
  1. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 9;387(10027):1551-60.
  1. Paiva B, Cedena MT, Puig N, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016 Jun 23;127(25):3165-74.
  1. Weisel KC, Dimopoulos MA, Moreau P, et al. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low – dose dexamethasone versus high – dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016 Jul;101(7):872-8.
  1. de la Puente P, Quan N, Hoo RS, et al. Newly Established Myeloma-Derived Stromal Cell Line MSP-1 Supports Multiple Myeloma Proliferation, Migration, And Adhesion And Induces Drug Resistance More Than Normal-Derived Stroma. Haematologica. 2016 Jul;101(7):e307-11.
  1. Drent E, Groen RW, Noort WA, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016 May;101(5):616-25.
  1. Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. See comment in PubMed Commons belowBr J Haematol. 2016 Jun 13.
  1. Mai EK, Benner A, Bertsch U,et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. See comment in PubMed Commons belowBr J Haematol. 2016 Jun;173(5):731-41.
  1. Kourelis TV, Buadi FK, Kumar SK,et al. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. Am J Hematol. 2016 Jun;91(6):585-9.
  1. Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 Jun;91(6):575-80.


Syndromes myélodysplasiques

Proposé par Sarah Morin et Jérôme Paillassa, supervisé par Sylvain Thépot. 

  1. Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescent. Blood. 2016 Mar 17;127(11):1387-97; quiz 1518.
  1. Mason CC, Khorashad JS, Tantravahi SK, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016 Apr;30(4):906-13.
  1. Garcia-Manero G, Gore SD, Kambhampati S, et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
  1. Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016 Apr;30(4):897-905.
  1. Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr;17(4):496-508.
  1. Finke J, Schmoor C, Bertz H, et al. Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016 Jun;51(6):771-7.
  1. Peffault de Latour R, Soulier J. How I treat MDS and AML in Fanconi anemia. Blood. 2016 Jun 16;127(24):2971-9
  1. Santini V, Almeida A, Giagounidis A, et al. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol. 2016 Jun 27.



Proposé par Nicolas Gendron et Clémence Roux, supervisé par David Smadja

  1. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016 Jun 25;387(10038):2605-13.
  1. Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016 Jul;14(7):1480-3.
  1. Bakchoul T, Jouni R, Warkentin TE. Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine/heparin antibodies. J Thromb Haemost. 2016 Jul 5.
  1. Wang Y, Zhao X, Lin J, et al. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. JAMA. 2016 Jul 5;316(1):70-8.
  1. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2016 Jun 13;5(6).
  1. Ruff CT, Giugliano RP, Antman EM. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation. 2016 Jul 19;134(3):248-61.
  1. Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation. 2016 Jul 5;134(1):37-47.
  1. Powell JR. Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. N Engl J Med. 2016 Jul 28;375(4):390.
  1. Blackshear JL, McRee CW, Safford RE, et al. Von Willebrand Factor Abnormalities and Heyde Syndrome in Dysfunctional Heart Valve Prostheses. JAMA Cardiol. 2016 May 1;1(2):198-204.
  1. Kopić A, Benamara K, Piskernik C, et al. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2016 Jul;14(7):1410-9.
  1. Mastrolia SA, Novack L, Thachil J, et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis. Thromb Haemost. 2016 Jul 21;116(4).


Leucémie lymphoïde chronique

Proposé par Claire Bréal et Florian Chevillon, supervisé par Loic Ysebaert 

  1. Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. 2016 Jun 23;127(25):3215-24.
  1. D’Avola A, Drennan S, Tracy I, et al. Surface IgM expression and function associate with clinical behavior, genetic abnormalities and DNA methylation in CLL. 2016 Jun 14.
  1. See comment in PubMed Commons belowInternational CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016 Jun;17(6):779-90.
  1. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-78.
  1. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. 2016 Apr 28;127(17):2122-30.
  1. Valsecchi R, Coltella N, Belloni D, et al. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. 2016 Apr 21;127(16):1987-9.
  1. Piszcz J, Armitage EG, Ferrarini A, et al. To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients. 2016 Apr 19;7(16):22324-38.
  1. Strati P, Uhm JH, Kaufmann TJ, et al. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. 2016 Apr;101(4):458-65.
  1. Rawstron AC, Fazi C, Agathangelidis A, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. 2016 Apr;30(4):929-36
  1. Oppermann S, Ylanko J, Shi Y, et al. Identification of kinase inhibitors that overcome venetoclax resistance in activated CLL cells by high-content screening. 2016 Jun 13.